title: Association between the hOGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis based on 22,475 subjects.
abstract: OBJECTIVE
  The Ser326Cys polymorphism in the human 8-oxogunaine glycosylase (hOGG1) gene with lung cancer susceptibility had been investigated, but results were inconsistent and underpowered. The aim of this study was to conduct a meta-analysis assessing the association of hOGG1 Ser326Cys polymorphism with risk of lung cancer.
  
  
  METHODS
  Relevant studies were identified through a search of MEDLINE, PubMed, Web of Science, EMBASE, and Chinese Biomedical Literature database (CBM) using terms "lung cancer", "hOGG1" or "OGG1", "polymorphism" or "variation" and the last search updated on May 1, 2013. In this meta-analysis, we assessed 30 published studies involving 22,475 subjects that investigated the association between the hOGG1 Ser326Cys polymorphism and lung cancer susceptibility.
  
  
  RESULTS
  Overall, the hOGG1 Ser326Cys polymorphism was not associated with lung cancer susceptibility in different genetic models (dominant model comparison: OR = 0.133; 95% CI = 0.111-0.161; P(heterogeneity) = 0.000), and recessive model: OR = 0.543; 95% CI = 0.399-0.739; P(heterogeneity) = 0.000). Similarly, in the stratified analyses by ethnicity, significantly increased risks were found among Asians for homozygote comparison (OR = 0.850; 95% CI = 0.732 0.986; P(heterogeneity) = 0.064), and dominant model (OR = 0.160; 95% CI = 0.137-0.187; P(heterogeneity) = 0.001), and Caucasians for dominant model (OR = 1.35; 95% CI = 1.03-1.77; P(heterogeneity) = 0.015), and recessive model (OR = 1.35; 95% CI = 1.03-1.77; P(heterogeneity) = 0.015). In population-based populations, marginally significant increased risks were found in dominant model (OR = 0.143; 95% CI = 0.111 0.184; P(heterogeneity) = 0.000) and recessive model (OR = 0.429; 95% CI = 0.261-0.705; P(heterogeneity) = 0.000). We also found a significant difference between hOGG1 Ser326Cys genotype and lung cancer susceptibility in studies with hospital-based controls for homozygote model (OR = 0.798; 95% CI = 0.649-0.982; P(heterogeneity )= 0.007),dominant model (OR = 0.122; 95% CI = 0.091-0.163; P(heterogeneity) = 0.000).
  
  
  CONCLUSIONS
  Our data showed that the hOGG1 Ser326Cys polymorphism contributed to the risk of lung cancer.
  The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3842531131031605.
authors: Department of Oncology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110003, China. zhaoguo_xu@126.com.
authors: Zhaoguo
authors: Z
authors: Xu
authors: Li
authors: L
authors: Yu
authors: Xiaoye
authors: X
authors: Zhang
mesh_terms: D016009:Chi-Square Distribution; D045647:DNA Glycosylases / Q000235:genetics*; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000208:ethnology / Q000235:genetics*; D016017:Odds Ratio; D010641:Phenotype; D011110:Polymorphism, Genetic; D044469:Racial Groups / Q000235:genetics; D012307:Risk Factors; D012694:Serine
chemical_list: D012694:Serine; D045647:DNA Glycosylases; C479058:oxoguanine glycosylase 1, human
references: J Natl Cancer Inst. 1989 Jan 18;81(2):107-15
references: 2642556
references: Diagn Pathol. 2012 Jul 20;7:87
references: 22818553
references: Am J Respir Crit Care Med. 2009 May 15;179(10):860-8
references: 19423719
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Carcinogenesis. 2006 Mar;27(3):560-7
references: 16195237
references: Diagn Pathol. 2013 May 24;8:89
references: 23706092
references: Arch Biochem Biophys. 2000 May 1;377(1):1-8
references: 10775435
references: Am J Epidemiol. 2009 Sep 15;170(6):695-702
references: 19671832
references: J Natl Cancer Inst. 2005 Apr 20;97(8):567-76
references: 15840879
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Mutat Res. 2007 Jul 28;631(2):101-10
references: 17531525
references: Pharmacogenetics. 2004 Feb;14(2):103-9
references: 15077011
references: Mutat Res. 2008 Mar 1;639(1-2):45-54
references: 18155253
references: Mutat Res. 2011 May 10;709-710:21-31
references: 21376741
references: J Biol Chem. 1992 Jan 5;267(1):166-72
references: 1730583
references: J Hum Genet. 2009 Dec;54(12):739-45
references: 19881468
references: Diagn Pathol. 2009 Mar 24;4:9
references: 19317905
references: Cancer Sci. 2006 Aug;97(8):724-8
references: 16800823
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Diagn Pathol. 2011 Jun 04;6:48
references: 21639921
references: Methods Enzymol. 1999;300:156-66
references: 9919519
references: Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1739-45
references: 18628426
references: Zhongguo Fei Ai Za Zhi. 2011 Mar;14(3):205-10
references: 21426661
references: J Exp Clin Cancer Res. 2009 Jan 22;28:10
references: 19161591
references: Am J Epidemiol. 2005 Nov 15;162(10):925-42
references: 16221808
references: Free Radic Res. 2006 Aug;40(8):885-91
references: 17015267
references: Cancer Epidemiol Biomarkers Prev. 1999 Aug;8(8):669-74
references: 10744126
references: Prog Nucleic Acid Res Mol Biol. 2001;68:193-205
references: 11554297
references: J Thorac Oncol. 2011 Apr;6(4):813-7
references: 21623257
references: Carcinogenesis. 2004 Nov;25(11):2177-81
references: 15284179
references: Carcinogenesis. 2000 Mar;21(3):361-70
references: 10688856
references: Carcinogenesis. 1990 Sep;11(9):1447-50
references: 2205403
references: Antioxid Redox Signal. 2001 Aug;3(4):597-609
references: 11554447
references: Arch Med Res. 2011 Apr;42(3):226-34
references: 21722819
references: Carcinogenesis. 2006 Jun;27(6):1245-50
references: 16364924
references: Ann Hum Genet. 1955 Jun;19(4):251-3
references: 14388528
references: Oncogene. 1998 Jun 25;16(25):3219-25
references: 9681819
references: Cancer Res. 2003 Mar 1;63(5):902-5
references: 12615700
references: Science. 1997 Nov 7;278(5340):1043-50
references: 9353177
references: Cancer Lett. 2005 Jun 8;223(2):265-74
references: 15896461
references: Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):730-8
references: 12163326
references: J Epidemiol. 2002 May;12(3):258-65
references: 12164330
references: Arh Hig Rada Toksikol. 2008 Dec;59(4):241-50
references: 19064361
references: Int J Cancer. 2000 Dec 15;88(6):932-7
references: 11093817
references: Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):409-12
references: 11927502
references: Biochem Genet. 2004 Dec;42(11-12):453-60
references: 15587988
references: Carcinogenesis. 2006 Dec;27(12):2448-54
references: 16774934
references: Carcinogenesis. 2006 May;27(5):997-1007
references: 16308313
references: Mol Carcinog. 2005 Mar;42(3):127-41
references: 15584022
references: Anticancer Res. 2010 Oct;30(10):4141-5
references: 21036733